SANOVO

1. 01:01
   ESMO 2026 现场信号

   #ScienceLink #Madrid2026 #ESMO26 #SANOVO #Savolitinib #Osimertinib

1. 21:31
   ESMO 2026 现场信号

   🫁 #ESMO26 Día 4 | Pulmón: la revolución en EGFRm tras progresión a TKI y co-alteración con MET
2. 21:30
   ESMO 2026 现场信号

   #ESMO26 Day 4: Midday Update
3. 20:25
   ESMO 2026 现场信号

   #ESMO26 | Dr. Rebecca Heist (@MGHThoracicOnc): Is MET testing the next step in personalized lung cancer treatment?
4. 20:24
   ESMO 2026 现场信号

   SANOVO: 1L EGFR-mutant, MET-overexpressing advanced NSCLC. Savolitinib + osimertinib vs osimertinib: median PFS 24.9 vs 13.8 months (HR 0.56). Primary PFS met. Should MET testing m
5. 18:56
   ESMO 2026 现场信号

   Positive Phase III SANOVO trial results at #ESMO26: 1L ORPATHYS® + TAGRISSO® reduced risk of progression or death by 44% overall and 55% in high MET overexpression, with encouragin
6. 18:25
   中文产业新闻精选

   SANOVO III期显示奥希替尼联合赛沃替尼一线治疗MET过表达的EGFR突变晚期NSCLC，PFS和OS均改善

   SANOVO III期显示，奥希替尼联合赛沃替尼一线治疗MET过表达EGFR突变晚期NSCLC，较奥希替尼单药使ITT人群进展或死亡风险降低44%。

7. 16:14
   ESMO 2026 现场信号

   SANOVO - New strategy to overcome MET resistance in mEGFR NSCLC
8. 15:47
   ESMO 2026 现场信号

   Y Wu: presenting SANOVO trial. Number of patients screened is enormous. Significant PFS 24 months vs 11.1 months and OS benefit HR 0.48! Minimal increase in AEs. Note increased MET
9. 15:42
   ESMO 2026 现场信号

   #ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs
10. 15:42
    ESMO 2026 现场信号

    SANOVO; front line savo osi in MET over-expressed common mEGFR; 3+ or 2+ (interesting definition); double blind with placebo control; screen 1896 to randomise 326; PFS HR 0.48 in 3
11. 15:42
    ESMO 2026 现场信号

    🚨 #ESMO26 SANOVO Ph3 🇨🇳 (China-only)

当前热度 95·可比范围峰值 99（10月26日 22:00）·近 24 小时可比范围变化 –·当前参与者 12

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。